Ahmed S. Alnughmush

Hematology

200 1st St Sw
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Journal: American journal of hematology

Published: May 30, 2026

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Journal: Bone marrow transplantation

Published: February 22, 2026

Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study.

Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study.

Journal: Cytotherapy

Published: October 21, 2025

Low (0.1% to ≤ 1%) or Very Low (0.06% to < 0.1%) JAK2V617F Allele Burden in Routine Testing: Clinical Correlates and Clonal Trajectory.

Low (0.1% to ≤ 1%) or Very Low (0.06% to < 0.1%) JAK2V617F Allele Burden in Routine Testing: Clinical Correlates and Clonal Trajectory.

Journal: American journal of hematology

Published: October 17, 2025

Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo Clinic.

Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo Clinic.

Journal: American journal of hematology

Published: September 25, 2025

Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis.

Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis.

Journal: British journal of haematology

Published: May 10, 2025

Association of Cyclosporine Exposure Post-Allogeneic Hematopoietic Cell Transplant With Graft Failure and Relapse Risk in Hematological Malignancies.

Association of Cyclosporine Exposure Post-Allogeneic Hematopoietic Cell Transplant With Graft Failure and Relapse Risk in Hematological Malignancies.

Journal: Transplantation and cellular therapy

Published: April 02, 2025

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.

Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.

Journal: Blood cancer journal

Published: March 31, 2025

Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.

Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.

Journal: European journal of haematology

Published: March 18, 2025

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?

Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?

Journal: Transplantation direct

Published: November 18, 2024

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.

Journal: Current oncology (Toronto, Ont.)

Published: November 05, 2024

Treatment of Late-onset Acute Graft-versus-host Disease Following Double Lung Transplantation Using a JAK2 Inhibitor.

Treatment of Late-onset Acute Graft-versus-host Disease Following Double Lung Transplantation Using a JAK2 Inhibitor.

Journal: Transplantation

Published: October 08, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026